#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review

Kyle LaHucik

Senior Reporter

NEW ORLEANS — Following up on two subsets presented Saturday, Eli Lilly’s Loxo Oncology fleshed out the data on its non-covalent BTK inhibitor pirtobrutinib in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents

#ASH22: Lil­ly’s Loxo rounds out the PhI/II da­ta for lym­phoma drug un­der FDA re­view

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents